WelcomeInnovation at St. Joe’sAddressing Gaps in Care

CONNECT-ILD

Boehringer Ingelheim Canada and the Firestone Institute for Respiratory Health (FIRH) are collaborating to bring an innovative health solution for patients living with interstitial lung disease (ILD) to address crucial care gaps. The CONNECT-ILD project will use innovative technology—Seamless MD—that enables remote patient management, peer-to-peer community support, patient education, and multi-disciplinary discussions to provide patients with another pathway to access the care they need.

An estimated 18 to 32 per cent of patients with an ILD will have their condition evolve to a progressive fibrosing-ILD (PF-ILD), leading to respiratory failure and death within three to five years from diagnosis. Regular monitoring is important for the early detection of patients with a progressive course of the disease.

“At the Firestone Institute for Respiratory Health, we’re excited for the launch of CONNECT-ILD as it approaches ILD care holistically and goes beyond managing physical symptoms,” says Dr. Martin Kolb, a respirologist at St. Joseph’s Healthcare Hamilton, Director of the Respirology Division at McMaster University, and Canada’s first research chair holder in interstitial lung disease. “By partnering to optimize care in an innovative, first-of-its-kind way, we are leveraging our strengths to collectively create sustainable and transformative healthcare solutions for patients.”

Clinicians at St. Joe’s Firestone Institute for Respiratory Health are piloting the CONNECT-ILD platform to improve the patient experience.

The collaboration uses the digital care journey platform—SeamlessMD—which was selected through a rigorous process from among 20 proposed solutions. The platform provides  patients with reminders, evidence-based education, progress tracking, symptom management, and allows for remote patient monitoring for patients who are diagnosed with ILD. The platform, accessible via app and web, features both patient and physician portals. The goals of the program are continuous monitoring of patients at higher risk of poor outcomes, reduced waitlist by limiting the need for in-person visits, and improved experience for patients and physicians.

A significant portion of the funding for this project was provided by the Ontario Centre of Innovation (OCI), which helps Ontario innovators connect with the researchers, industry partners, and funding needed to commercialize the next generation of made-in-Ontario IP and solutions.

Sharon Lee, Executive Director of the Canadian Pulmonary Fibrosis Foundation

The Canadian Pulmonary Fibrosis Foundation is proud to be involved in this innovative partnership that transforms patient care and connects patients and caregivers to their care team. By addressing the unmet needs of people living with ILD, and providing them access to personalized support, they can receive the care they need through every step of their ILD journey.

One of the major components behind this innovation is the key collaboration between a leading research centre, a digital care platform creator and industry, through a collaborative process enabled by MEDTEQ+—a pan-Canadian Consortium accelerating the development and commercialization of innovative technological solutions developed by the Canadian health technologies industry—to improve the lives of patients.

“With this collaboration, we aim to make a positive impact for those with ILD and drive sustainable and transformative health system change,” says Annie Beauchemin, Executive Director, Patient Access and Healthcare Solutions for Boehringer Ingelheim Canada. “By embracing the power of partnership and the diversity of experts in the scientific community, we can develop more innovative solutions together and improve patient outcomes.”

About Seamless MD

SeamlessMD provides the leading Digital Care Journey platform for hospitals and health systems to engage, monitor and stay connected with patients across healthcare journeys. 30+ clinical studies & evaluations have shown SeamlessMD to improve the patient experience while reducing hospital length of stay, readmissions, and ED visits. Health systems such as Trillium Health Partners, SE Health, William Osler Health System, Sunnybrook, Grand River Hospital, St. Joseph’s Healthcare, Nova Scotia Health Authority and others use SeamlessMD to elevate the patient experience, improve outcomes and lower costs. Patients access digital care plans on their smartphones, tablets or computers and are guided via reminders, education, and progress tracking. Providers receive alerts, monitor patients and access analytics to deliver better care. SeamlessMD is directly integrated with EHRs such as Epic, Cerner, and MEDITECH. Learn more at https://seamless.md/

About OCI

For more than 35 years, OCI has played a key role in the innovation ecosystem, from catalyzing innovation through industry- academic partnerships to connecting collaborators across the province, with the vision of being at the centre of innovation in Ontario – driving economic growth and job creation through investments in the commercialization and adoption of new technologies.

OCI builds bridges between sectors, sparking vibrant collaborations that lead to the creation of products and jobs that make a real impact in the lives of Ontarians now and into the future. OCI helps ensure Ontario is where next happens. We accelerate job creation through innovation, commercializing game-changing research by connecting industry and  academia. https://www.oc-innovation.ca/

About MEDTEQ+

The mission of the Pan-Canadian Consortium for Industrial Research and Innovation in Medical Technologies (MEDTEQ+) is to accelerate the development of innovative technological solutions to improve the health status and quality of life of patients. MEDTEQ+ supports the validation of these technologies, their integration into the healthcare network, and their local and international outreach by bringing together the complementary skills of industrial and institutional partners and healthcare providers. MEDTEQ+ relies on the financial support of the Government of Quebec, the Government of Canada (through the Centres of Excellence for Commercialization and Research (CECR) program), the private sector, and complementary partners to foster research-industry relationships. https://www.medteq.ca/